Analysts expect that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will post sales of $592.47 million for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Vertex Pharmaceuticals’ earnings, with estimates ranging from $565.68 million to $634.20 million. Vertex Pharmaceuticals reported sales of $458.71 million during the same quarter last year, which would indicate a positive year over year growth rate of 29.2%. The firm is scheduled to announce its next quarterly earnings report on Wednesday, January 24th.

On average, analysts expect that Vertex Pharmaceuticals will report full-year sales of $592.47 million for the current year, with estimates ranging from $2.13 billion to $2.47 billion. For the next fiscal year, analysts forecast that the company will post sales of $2.70 billion per share, with estimates ranging from $2.53 billion to $2.85 billion. Zacks’ sales averages are a mean average based on a survey of research analysts that follow Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 EPS.

VRTX has been the subject of a number of research analyst reports. Cowen and Company reissued a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Credit Suisse Group lifted their price objective on Vertex Pharmaceuticals from $125.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, July 19th. DA Davidson began coverage on Vertex Pharmaceuticals in a report on Friday, September 29th. They issued a “buy” rating and a $200.00 price objective for the company. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $173.15.

In related news, COO Ian F. Smith sold 2,155 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $150.00, for a total value of $323,250.00. Following the sale, the chief operating officer now directly owns 43,043 shares in the company, valued at $6,456,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Parini sold 2,330 shares of the business’s stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $149.50, for a total value of $348,335.00. Following the completion of the sale, the executive vice president now owns 31,139 shares in the company, valued at $4,655,280.50. The disclosure for this sale can be found here. Insiders sold 220,094 shares of company stock worth $32,074,719 over the last quarter. 1.80% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,504 shares of the pharmaceutical company’s stock worth $2,385,000 after buying an additional 75 shares in the last quarter. Buckingham Asset Management LLC increased its stake in Vertex Pharmaceuticals by 3.6% during the second quarter. Buckingham Asset Management LLC now owns 2,265 shares of the pharmaceutical company’s stock worth $292,000 after acquiring an additional 79 shares during the last quarter. Eqis Capital Management Inc. increased its stake in Vertex Pharmaceuticals by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 14,549 shares of the pharmaceutical company’s stock worth $1,875,000 after acquiring an additional 83 shares during the last quarter. Grandfield & Dodd LLC increased its stake in Vertex Pharmaceuticals by 1.6% during the second quarter. Grandfield & Dodd LLC now owns 5,805 shares of the pharmaceutical company’s stock worth $748,000 after acquiring an additional 90 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in Vertex Pharmaceuticals by 0.7% during the second quarter. Louisiana State Employees Retirement System now owns 15,400 shares of the pharmaceutical company’s stock worth $1,985,000 after acquiring an additional 100 shares during the last quarter. Institutional investors own 93.06% of the company’s stock.

Vertex Pharmaceuticals (NASDAQ VRTX) traded up $0.57 during trading on Wednesday, hitting $148.74. The company’s stock had a trading volume of 861,000 shares, compared to its average volume of 1,829,104. The company has a market cap of $37,472.61, a price-to-earnings ratio of 246.95, a price-to-earnings-growth ratio of 3.76 and a beta of 1.63. Vertex Pharmaceuticals has a twelve month low of $71.46 and a twelve month high of $167.85. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01.

WARNING: “Brokerages Anticipate Vertex Pharmaceuticals Incorporated (VRTX) Will Announce Quarterly Sales of $592.47 Million” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/11/brokerages-anticipate-vertex-pharmaceuticals-incorporated-vrtx-will-announce-quarterly-sales-of-592-47-million.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get a free copy of the Zacks research report on Vertex Pharmaceuticals (VRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Stock Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related stocks with our FREE daily email newsletter.